Cardiff Oncology presents onvansertib data: 73% DCR in 2L KRAS-mut mCRC; FDA Type C meeting supports accelerated path

Cardiff Oncology, Inc.

73% disease control rate in 2L KRAS-mutated mCRC; median overall survival 15 months vs ~8 months historical.
FDA Type C meeting (June 2023) agreed on mCRC development plan supporting potential accelerated approval.
Topline data from 1st-line RAS-mutated mCRC trial expected mid-2024.
Cash runway extends into 2025; collaboration with Pfizer under Pfizer Ignite program.
Preclinical data show onvansertib + bevacizumab reduces tumor size and vascularization in KRAS G12V model.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.